A Novel Combination of Methotrexate and Epigallocatechin Attenuates the Overexpression of Pro-inflammatory Cartilage Cytokines and Modulates Antioxidant Status in Adjuvant Arthritic Rats

详细信息    查看全文

• 作者：Souvik Roy (1) souvikroy35@gmail.com
  Santanu Sannigrahi (1)
  Ram Prasad Vaddepalli (2)
  Balaram Ghosh (3)
  Priyanka Pusp (4)
• 关键词：KEY WORDS methotrexate &#8211 ; epigallocatechin &#8211 ; adjuvant arthritis &#8211 ; cytokines &#8211 ; antioxidant
• 刊名：Inflammation
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：35
• 期：4
• 页码：1435-1447
• 全文大小：613.6 KB
• 参考文献：1. Firestein, G.S. 2003. Evolving concept of rheumatoid arthritis. Nature 423: 356–361. doi:
  2. Mathew, A.J., J. Antony, S. Eremenco, B.V. Paul, B. Jayakumar, and J. Philip. 2009. Health-related quality of life in rheumatoid arthritis patients in South India. Singapore Medical Journal 50: 800–803. PMID: 19710980.
  3. Wortmann, R.L. 1991. Pathogenesis of rheumatoid arthritis: Basis for future therapies. Seminars in Arthritis and Rheumatism 21(suppl): 35–39. PMID: 1749947.
  4. Zvaifler, N.J. 1988. New perspectives on the pathogenesis of rheumatoid arthritis. American Journal of Medicine 85(suppl): 12–17. PMID: 3052052.
  5. Hassan, M.Q., R.A. Hadi, Z.S. Al-Rawi, V.A. Padron, and S.J. Stohs. 2001. The glutathione defense system in the pathogenesis of rheumatoid arthritis. Journal of Applied Toxicology 21: 69–73. doi:
  6. Heliovaara, M., P. Knekt, K. Aho, R.K. Aaran, G. Alfthan, and A. Aromaa. 1994. Serum antioxidants and risk of rheumatoid arthritis. Annals of the Rheumatic Diseases 53: 51–53. PMID: 8311556.
  7. Jaswal, S., H.C. Mehta, A.K. Sood, and J. Kaur. 2003. Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clinica Chimica Acta 338: 123–129. PMID: 14637276.
  8. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14: 397–440. doi:
  9. Chu, C.Q., M. Field, M. Feldmann, and R.N. Maini. 1991. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis and Rheumatism 34: 1125–1232. PMID: 1930331.
  10. Farahat, M.M., G. Yanni, R. Poston, and G.S. Panayi. 1993. Cytokine expression in synovial membrane of patients with rheumatoid arthritis & osteoarthritis. Annals of the Rheumatic Diseases 52: 870–875. PMID: 8311538.
  11. Nishimoto, N. 2006. Interleukin-6 in rheumatoid arthritis. Current Opinion in Rheumatology 18: 277–281. PMID: 16582692.
  12. Akira, S., T. Taga, and T. Kishimoto. 1993. Interleukin-6 in biology and medicine. Advances in Immunology 54: 1–78. PMID: 8379461.
  13. Kishimoto, T. 2005. IL-6: From laboratory to bedside. Clinical Reviews in Allergy & Immunology 28: 177–186. doi:
  14. Benslay, D.N., and A.M. Bendele. 1991. Development of a rapid screen for detecting and differentiating immunomodulatory vs anti-inflammatory compounds in rats. Agents and Actions 34: 254–256. PMID: 1793040.
  15. Halloran, M.M., J.M. Woods, Z. Szekanecz, N. Barquin, G.K. Haines, A. Walz, and A.E. Koch. 1999. The role of an epithelial neutrophil-activating peptide-78-like protein in rat adjuvant-induced arthritis. Journal of Immunology 162: 7492–7500. PMID: 10358204.
  16. Billiau, A., and P. Matthys. 2001. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. Journal of Leukocyte Biology 70: 849–860. PMID: 11739546.
  17. Braun, J., and R. Rau. 2009. An update on methotrexate. Current Opinion in Rheumatology 21: 216–223. PMID: 19373092.
  18. Cronstein, B.N. 2005. Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis. Pharmacological Reviews 57: 163–172. doi:
  19. Joannides, A.J., H. El-Shaboury, R. Guirguis, J.J. Fasler, and V. Rajagopal. 2011. Methotrexate-associated lymphoproliferative disorder presenting as disseminated malignancy. Rheumatology 50: 1927–1928. doi:
  20. MCkendry, R.J., and P. Dale. 1993. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. Journal of Rheumatology 20: 1850–1856. PMID: 8308769.
  21. Smolen, J.S., D. Aletaha, J.W. Bijlsma, F.C. Breedveld, D. Boumpas, G. Burmester, B. Combe, M. Cutolo, M. de Wit, M. Dougados, P. Emery, A. Gibofsky, J.J. Gomez-Reino, B. Haraoui, J. Kalden, E.C. Keystone, T.K. Kvien, I. McInnes, E. Martin-Mola, C. Montecucco, M. Schoels, and D. van der Heijde. 2010. Treating rheumatoid arthritis to target: Recommendations of an international task force. Annals of the Rheumatic Diseases 69: 631–637. doi:
  22. Weinblatt, M.E., J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, C.G. Jackson, M. Lange, and D.J. Burge. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. The New England Journal of Medicine 340: 253–259. PMID: 9920948.
  23. Trevisanato, S.I., and Y.I. Kim. 2000. Tea and health. Nutrition Reviews 58: 1–10. PMID: 10697388.
  24. Yang, C.S., and Z.Y. Wang. 1993. Tea and cancer. Journal of the National Cancer Institute 85: 1038–1049. doi:
  25. Katiyar, S.K., and C.A. Elmets. 2001. Green tea polyphenolic antioxidants and skin photo protection. International Journal of Oncology 18: 1307–1313. PMID: 11351267.
  26. Lin, Y.L., and J.K. Lin. 1997. Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by downregulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Molecular Pharmacology 52: 465–472. PMID: 9281609.
  27. Sachinidis, A., R.A. Skach, C. Seul, Y. Ko, J. Hescheler, H.Y. Ahn, and J. Fingerle. 2002. Inhibition of the PDGF beta-receptor tyrosine phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins. The FASEB Journal 16: 893–895. PMID: 12039871.
  28. Mukhtar, H., and N. Ahmad. 2000. Tea Polyphenols: Prevention of cancer and optimizing health. American Journal of Clinical Nutrition 71: 1698S–1702S. PMID: 10837321.
  29. Constantin, A., P. Loubet-lescoulie, N. Lambert, and A. Cantagrel. 1998. Anti-inflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis and Rheumatism 41: 48–57. doi:
  30. Chesbrough, M., and J. McArthur. 1972. Laboratory manual of rural tropical hospitals. Churchil: The English Language Book Society.
  31. David, G., and A.J. Sykes. 1951. Westergren and Wintrobe methods of estimating ESR compared. British Medical Journal 2: 1496–1497. PMID: 14886634.
  32. Balasubramaniam, P., and A. Malathi. 1992. Comparative study of hemoglobin estimated by Drabkin’s and Sahli’s methods. Journal of Postgraduate Medicine 38: 8–9. PMID: 1512732.
  33. Okhawa, H., N. Oishi, and K. Yagi. 1979. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Analytical Biochemistry 95: 351–358. PMID: 36810.
  34. Ellman, G.L. 1959. Tissue sulphydril groups. Archives of Biochemistry and Biophysics 82: 70–77. PMID: 13650640.
  35. Kakkar, P., B. Das, and P.N. Viswanthan. 1984. A modified spectrophotometric assay of superoxide dismutase. Indian Journal of Biochemistry & Biophysics 21: 130–132. PMID: 6490072.
  36. Narendhirakannan, R.T., S. Subramanian, and M. Kandaswamy. 2005. Free radical scavenging activity of Cleome gynandra L. leaves on adjuvant induced arthritis in rats. Molecular and Cellular Biochemistry 276: 71–80. doi:
  37. Hegen, M., J.C. Keith, M. Collins, and C.L. Nickerson-Nutter. 2008. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Annals of the Rheumatic Diseases 67: 1505–1515. PMID: 18055474.
  38. Bevaart, L., M.J. Vervoordeldonk, and P.P. Tak. 2010. Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis? Arthritis and Rheumatism 62: 2192–2205. doi:
  39. Quinones, M.P., S.K. Ahuja, F. Jimenez, J. Schaefer, E. Garavito, A. Rao, G. Chenaux, R.L. Reddick, W.A. Kuziel, and S.S. Ahuja. 2004. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. The Journal of Clinical Investigation 113: 856–866. doi:
  40. Altman, A., and F.J. Dixon. 1989. Immunomodifiers in vaccines. Advances in Veterinary Science and Comparative Medicine 33: 301–343. PMID: 2467538.
  41. Crofford, L.J., H. Sano, K. Karalis, E.L. Webster, E.A. Goldmuntz, G.P. Chrousos, and R.L. Wilder. 1992. Local secretion of corticotrophin releasing hormone in the joints of Lewis rats with inflammatory arthritis. The Journal of Clinical Investigation 90: 2555–2564. doi:
  42. Linblad, E.B. 2000. Freund’s adjuvants. In Methods in molecular medicine: Vaccine adjuvants—preparation methods and research protocols, ed. D.T. O’ Hagan, 49–63. Totowa: Humana Press.
  43. Cannella, A.C., and J.R. O’Dell. 2003. Is there still a role for traditional disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis? Current Opinion in Rheumatology 15: 185–192. PMID: 12707569.
  44. Swierkot, J., and J. Szechinski. 2006. Methotrexate in rheumatoid arthritis. Pharmacological Reports 58: 473–492. PMID: 16963793.
  45. Rovensky, J., M. Stancikova, E. Rovenska, S. Stvrtina, V. Stvrtinova, and K. Svik. 2009. Treatment of rat adjuvant arthritis with flavonoid (Detralex), methotrexate, and their combination. Annals of the New York Academy of Sciences 1173: 798–804. doi:
  46. Alastair, G., and M.B. Mowat. 1971. Hematological abnormalities in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 1: 195–219. doi:10.1016/0049-0172(72)90001-7. PMID: 4343443.
  47. Sotnikova, R., S. Ponist, J. Navarova, D. Mihalova, V. Tomekova, M. Strosova, and K. Bauerova. 2009. Effects of sesame oil in the model of adjuvant arthritis. Neuro Endocrinology Letters 30: 22–24. PMID: 20027138.
  48. Ekambaram, S.P., S.S. Perumal, and V. Subramanian. 2011. Assessment of the in-vivo and in-vitro antioxidant potential of Strychnos potatorum Linn. seeds in Freund’s adjuvant induced arthritic rats. Journal of Medicinal Plants Research 5: 4780–4787.
  49. Karatas, F., I. Ozates, H. Canatan, I. Halifeoglu, M. Karatepe, and R. Colakt. 2003. Antioxidant status and lipid peroxidation in patients with rheumatoid arthritis. Indian Journal of Medical Research 118: 178–181. PMID:14700353.
  50. Bauerov谩, K., S. Poništ, D. Mihalov谩, F. Dr谩fi, and V. Kunc铆rov谩. 2011. Utilization of adjuvant arthritis model for evaluation of new approaches in rheumatoid arthritis therapy focused on regulation of immune processes and oxidative stress. Interdisciplinary Toxicology 4: 33–39. doi:
  51. Cong, X. D., M. J. Ding, D. Z. Dai, Y. Wu, Y. Zhang, and Y. Dai. 2011. ER Stress, P66shc, and P-Akt/Akt mediate adjuvant-induced inflammation, which is blunted by argirein, a supermolecule and rhein in Rats. Inflammation PMID: 22095404. doi:10.1007/s10753-011-9407-4.
  52. Guerne, P.A., B.L. Zuraw, J.H. Vaughan, D.A. Carson, and M. Lotz. 1989. Synovium as a source of interleukin 6 in vitro: Contribution to local and systemic manifestations of arthritis. The Journal of Clinical Investigation 83: 585–592. doi:
  53. Nietfeld, J.J., B. Wilbrink, M. Helle, J.L.A.M. Vanroy, R.W. Denotter, A.J.G. Swaak, and O. Huber-Bruning. 1990. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis and Rheumatism 33: 1695–1701. PMID: 2242066.
  54. Deleuran, B.W., C.Q. Chu, M. Field, F.M. Brennan, P. Katsiki, M. Feldmann, and R.N. Maini. 1992. Localization of interleukin-1 a, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. British Journal of Rheumatology 31: 809–811. doi:
• 作者单位：1. Department of Pharmaceutical Technology, NSHM Knowledge Campus, 124 B.L. Saha Road, Kolkata, 700053 West Bengal, India2. St. Peter鈥檚 Institute of Pharmaceutical Sciences, Hanmakonda, Warangal, Andhra Pradesh 506001, India3. Department of Pharmacology, Medical College Kolkata, West Bengal, Kolkata 700012, India4. Galaxy Concept Pvt. Ltd., Behala, Kolkata, 700034 West Bengal, India
• ISSN：1573-2576

文摘

The present study was designed to evaluate the combinatory effect of methotrexate (MTX) and epigallocatechin (EGCG) on the progression of adjuvant-induced arthritis in rats. Adjuvant arthritis (AA) was induced by a single intradermal injection of Freund’s complete adjuvant. AA rats were treated with methotrexate (0.3 mg/kg) thrice a week, EGCG (100 mg/kg) daily, and combination of MTX and EGCG thrice a week for a period of 28 days. Paw swelling changes and histopathological and radiographic analysis was assessed to evaluate the antiarthritic effect. Lipid peroxidation and antioxidant enzyme activities in joint tissue homogenate were performed to observe the modulation of antioxidant status along the expression of different pro-inflammatory cartilage cytokines like TNF-α and IL-6. MTX and EGCG combination potentiated both the antiarthritic (decrease of hind paw volume) and the antioxidant effect (SOD, GSH, and catalase) as well as suppression of lipid peroxidation. Combination therapy of MTX and EGCG significantly inhibited the development phase of arthritis, which is supported by histopathological, radiographical, and attenuation of overexpression of cartilage cytokines. EGCG act as potent antioxidant and immunomodulator, suggesting that combined administration of MTX along with EGCG suppressed the development phase of arthritic progression in rats.